UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 13-39 ...

Nephros, Inc. (NASDAQ:NEPH) Q4 2021 Earnings Conference Call February 23, 2022 4:30 PM ET Company Participants Kirin Smith ??? PCG Advisory Andy Astor ??? President & Chief Executive Officer Wes Lobo ??? Chief Commercial Officer Conference Call Participants Marc Wiesenberger ??? B. Riley Securities Anthony Vendetti ??? Maxim Group Neil Cataldi ??? Blueprint Capital Jason Hirschman ??? Hudson 2-15 Capital Operator Good day and welcome to the Nephros, Inc. Fourth Quarter 2021 Financial Results Conference Call ...

Nephros, Inc. (NASDAQ:NEPH) Q4 2020 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Andy Astor - President & Chief Executive Officer Kirin Smith - PCG Advisory Conference Call Participants Marc Wiesenberger - B Riley Securities Ralph Weil - R. Weil Investment Management Operator Good day and welcome to Nephros, Inc. Third Quarter 2021 Financial Results conference call. [Operator Instructions] I would now like to turn the conference over to Mr. Kirin Smith. Please proceed. Kirin Smi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

Financial Data and Key Metrics Changes - Nephros reported consolidated net revenues of $2.3 million for Q2 2021, a 44% increase compared to the same period in 2020 [16] - The net consolidated loss for the quarter was $1.1 million, improving by 35% from a loss of $1.7 million in 2020 [16] - Consolidated adjusted EBITDA was negative $0.8 million, a 46% improvement from negative $1.4 million in 2020 [16] - Consolidated gross margins were 56%, slightly down from 57% in 2020, with expectations to maintain margins between 55% to 60% in the future [16] Business Line Data and Key Metrics Changes - The Water Filtration business saw net filtration revenue increase by 40% year-over-year [10] - The Pathogen Detection Systems (PDS) business demonstrated early commercial success, with technology deployed at multiple customer locations [13] - The Renal Products segment submitted a 510(k) clearance application to the FDA for its second-generation HDF product, with expectations for clearance in the coming months [15] Market Data and Key Metrics Changes - The company noted a marked increase in face-to-face customer sales meetings and service engagements, indicating a strengthening business pipeline [12] - The new water management standards approved by CMS are expected to drive increased customer interest and demand for filtration and pathogen detection solutions [12] Company Strategy and Development Direction - Nephros acquired GenArraytion, Inc. to enhance its capabilities in infection disease monitoring and to vertically integrate its product offerings [14] - The company remains focused on long-term growth, particularly in water management programs for healthcare facilities, as new regulations come into effect [12] Management Comments on Operating Environment and Future Outlook - Management expressed optimism for the second half of the year but acknowledged potential downward pressure from the COVID-19 Delta variant [9] - The company is positioned to support healthcare facilities in meeting new water management requirements, which are set to begin in January 2022 [12] Other Important Information - The emergency response business has shown signs of recovery, although it remains subject to fluctuations based on outbreak sizes and hospital needs [21][22] - The dialysis business, including in-home dialysis, has been a significant growth area for the company [24] Q&A Session Summary Question: Dynamics of the emergency response business and reasons for slower rebound - Management noted that the emergency response business has rebounded from 2020, with increased attention on diseases other than COVID-19 contributing to this recovery [21] Question: Involvement in the in-home dialysis market - Nephros is involved in providing filters for in-home dialysis and has seen strong growth in this segment, which is expected to continue [24] Question: Impetus behind the GenArraytion acquisition and its impact on gross margins - The acquisition was a vertical integration strategy aimed at reducing development costs and time to market, which is expected to positively impact gross margins [25][26]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR (State or other jurisdiction of incorporation or organization) 380 Lackawanna Place (Address of principal executive offices) (Zip Code) South Orange, NJ 07079 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: ...

Nephros, Inc. (NASDAQ:NEPH) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Group, Investor Relations Andy Astor - Chief Executive Officer Conference Call Participants Martin Roth - Ferret Capital Management Robert Smith - Center for Performance Investing Marc Wiesenberger - B. Riley FBR Bob Wasserman - Benchmark Michael Brcic - National Securities Operator Good day and welcome to the Nephros First Quarter 2021 Financial Results Conference Call. All pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

Nephros, Inc. (NASDAQ:NEPH) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Group, Investor Relations Andy Astor - Chief Executive Officer Wes Lobo - Chief Marketing Officer Conference Call Participants Marc Wiesenberger - B Riley FBR Anthony Vendetti - Maxim Group Operator Good afternoon. And welcome to the Nephros Incorporated Fourth Quarter 2020 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions ...